Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro

Nuclear Medicine and Biology

Volumn 34, Issue 8, 2007, Pages 955-960

  Smith, Tim A D ^a   Sharma, Rituka I ^a   Wang, Weiguang G ^a,b   Welch, Andy E ^a   Schweiger, Lutz F ^a   Collie Duguid, Elaina S R ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

FDG; Glucose transport; MCF7 cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 10; GLUCOSE TRANSPORTER 8; HEXOKINASE; PHLORETIN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CELL CLONE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; ACTIVE TRANSPORT; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT, ACTIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; GLUCOSE; HUMANS; METABOLIC CLEARANCE RATE; RADIOPHARMACEUTICALS;

EID: 35848958349     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.07.007     Document Type: Article

References (25)

1. Goldie J.H. Drug resistance in cancer: a perspective. Cancer Metastasis Rev 20 (2001) 63-68
2. Moreno-Sanchez R., Rodriguez-Enriquez S., Marin-Hernandez A., and Saavedra E. Energy metabolism in tumor cells. FEBS J 274 (2007) 1393-1418
3. Smith T.A.D., Sharma R.I., Thompson A.M., and Paulin F.E.M. Tumor F-18-FDG incorporation is enhanced by attenuation of p53 function in breast cancer cells in vitro. J Nucl Med 47 (2006) 1525-1530
4. Caraco C., Aloj L., Chen L.Y., Chou J.Y., and Eckelman W.C. Cellular release of [F-18]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 275 (2000) 18489-18494
5. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H.S., Coleman R.E., and Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 42 (2001) 1S-93S
6. El-Khoueiry A.B., and Lenz H.J. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?. Cancer Invest 24 (2006) 50-55
7. Colozzaa M., de Azambuja E., Cardoso F., Bernard C., and Piccart M.J. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 11 (2006) 111-125
8. Mauritz R., van Groeningen C.J., Smid K., Jansen G., Pinedo H.M., and Peters G.J. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. Int J Cancer 120 (2007) 2609-2612
9. Wang W.G., Cassidy J., O'Brien V., Ryan K.M., and Collie-Duguid E. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 64 (2004) 8167-8176
10. Miccoli L., Oudard S., Sureau F., Poirson F., Dutrillaux B., and Poupon M.F. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J 313 (1996) 957-962
11. Reyes A.M., Bustamante F., Rivas C.I., Ortega M., Donnet C., Rossi J.P., et al. Nicotinamide is not a substrate of the facilitative hexose transporter GLUT1. Biochemistry 41 (2002) 8075-8081
12. Smith T.A.D. The rate-limiting step for tumor [F-18] fluoro-2-deoxy-d-glucose (FDG) incorporation. Nucl Med Biol 28 (2001) 1-4
13. Torizuka T., Zasadny K.R., Recker B., and Wahl R.L. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 207 (1998) 767-774
14. Shin Y.K., Yoo B.C., Chang H.J., Jeon E., Hong S.H., Jung N.S., et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65 (2005) 3162-3170
15. Hakata T., Ito K., and Horie T. Enhanced absorption of 3-O-methyl glucose following gastrointestinal injury induced by repeated oral administration of 5-FU in mice. J Pharm Sci 94 (2005) 1713-1722
16. Hwang J.T., Ha J., and Park O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 332 (2005) 433-440
17. 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47 (2006) 603-608
18. Smith T.A.D. Facilitative glucose transporters in human cancer tissue. Br J Biomed Sci 56 (1999) 285-292
19. Airley R.E., Phillips R.M., Evans A.E., Double J., Burger A.M., Feibig H.H., et al. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol 26 (2005) 1477-1484
20. Cloherty E.K., Heard K.S., and Carruthers A. Human erythrocyte sugar transport is incompatible with available carrier models. Biochemistry 35 (1996) 10411-10421
21. Martin H.J., Kornmann F., and Fuhrmann G.F. The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chem-Biol Interact 146 (2003) 225-235
22. Fuhrmann G.F., Derdenne S., and Frenking G. Phloretin keto-enol tautomerism and inhibition of glucose transport in human erythrocytes (including effects of phloretin on anion transport. Biochem Biophys Acta 1110 (1992) 105-111
23. Blodgett D.M., and Carruthers A. Conventional transport assays underestimate sugar transport rates in human red cells. Blood Cells Mol Dis 32 (2004) 401-407
24. Csala M., Banhegyi G., and Benedetti A. Endoplasmic reticulum: a metabolic compartment. FEBS Lett 580 (2006) 2160-2165
25. Chung J.H., Cho K.J., Lee S.S., Baek H.J., Park J.H., Cheon G.J., et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive 18F-FDG PET results in lung cancer staging. J Nucl Med 45 (2004) 999-1003